Alzamend Neuro, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALZN research report →
Companywww.alzamend.com
Alzamend Neuro, Inc. , an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.
- CEO
- Stephan Jackman
- IPO
- 2021
- Employees
- 4
- HQ
- Atlanta, GA, US
Price Chart
Valuation
- Market Cap
- $3.77M
- P/E
- -0.65
- P/S
- 0.00
- P/B
- 2.09
- EV/EBITDA
- -0.15
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -177.48%
- ROIC
- -322.04%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-4,514,853 · 54.62%
- EPS
- $-11.32 · 91.45%
- Op Income
- $-4,496,824
- FCF YoY
- 18.40%
Performance & Tape
- 52W High
- $8.22
- 52W Low
- $0.84
- 50D MA
- $1.27
- 200D MA
- $2.00
- Beta
- 0.11
- Avg Volume
- 126.71K
Get TickerSpark's AI analysis on ALZN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 14, 26 | AULT MILTON C III | buy | 108,388 |
| Dec 23, 25 | AULT MILTON C III | sell | 1,851 |
| Dec 19, 25 | Horne William B. | sell | 3,333 |
| Oct 23, 25 | McGrath Lynne Fahey | sell | 30 |
| Oct 8, 25 | AULT MILTON C III | other | 61,743 |
| Oct 8, 25 | AULT MILTON C III | sell | 101,394 |
| Oct 9, 25 | AULT MILTON C III | sell | 20,397 |
| Oct 8, 25 | AULT MILTON C III | other | 143.245 |
| Oct 7, 25 | AULT MILTON C III | other | 100,000 |
| Oct 3, 25 | AULT MILTON C III | other | 100,000 |
Our ALZN Coverage
We haven't published any research on ALZN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ALZN Report →